HIK.L - Hikma Pharmaceuticals PLC

LSE - LSE Delayed Price. Currency in GBp
1,676.00
-15.00 (-0.89%)
As of 11:13AM BST. Market open.
Stock chart is not supported by your current browser
Previous Close1,691.00
Open1,711.00
Bid1,674.50 x 16300
Ask1,676.00 x 34600
Day's Range1,657.98 - 1,711.00
52 Week Range1,399.00 - 2,089.00
Volume108,738
Avg. Volume773,696
Market Cap4.059B
Beta (3Y Monthly)0.59
PE Ratio (TTM)14.39
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.40 (2.28%)
Ex-Dividend Date2019-04-04
1y Target EstN/A
All
News
Press Releases
  • PR Newswire25 days ago

    Hikma Ventures participates in $11 million funding round for Pillo Health

    LONDON, May 30, 2019 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma) (HIK.L) (NASDAQ Dubai: HIK) (HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable) today announced its venture capital arm Hikma Ventures has participated in an $11 million financing round for Boston-based Pillo Health. The Series A round, led by Stanley Black & Decker's corporate venture capital arm with participation from Samsung Ventures and existing investors BioAdvance, Hackensack Meridian Health System's Innovation Center Fund and Civilization Ventures, will be used to drive growth and innovation as Pillo Health builds out its voice-enabled medication and care management platform for home use. "Our investment in Pillo Health underscores our deep commitment to developing innovative healthcare technology solutions that will put better health within reach for more patients around the world," said Lana Ghanem, Managing Director Hikma Ventures.

  • Pillo Health Raises $11M in Series-A Funding from Stanley Black & Decker and Samsung Ventures to Fuel Development of Voice-First Healthcare Platform for the Home
    PR Newswire26 days ago

    Pillo Health Raises $11M in Series-A Funding from Stanley Black & Decker and Samsung Ventures to Fuel Development of Voice-First Healthcare Platform for the Home

    BOSTON, May 29, 2019 /PRNewswire/ -- Pillo Health, a Boston-based technology company improving longevity and quality of life for patients managing their health at home, today announced that is has secured $11 million in funding from leading venture investors to complete its Series-A round. The capital will be used to drive growth and innovation as Pillo Health builds out its voice-enabled medication and care management platform for the home.

  • PR Newswire2 months ago

    Hikma Sponsors MIT Grand Hack to Support Global Healthcare Innovation

    The Grand Hack is MIT Hacking Medicine's annual flagship event dedicated to energise, infect and teach healthcare entrepreneurship and digital strategies to scale medicine as a way to solve health problems worldwide.  More than 500 participants, mentors and sponsors from 25 US states and 29 countries are expected to gather on campus in the MIT Media Lab for this year's Grand Hack, the largest healthcare hackathon in the US. As a strategic sponsor, Hikma and its venture capital arm Hikma Ventures will support the Grand Hack's 'Personalised Medicine' theme, which focuses on solving challenges in improving preventative medicine, treatment affordability and personalised medicine dosages.  Hikma will also have representatives on-site to speak with those attendees interested in exploring opportunities to join Hikma in its mission of putting better health within reach of millions of people through its high-quality medicines and healthcare solutions.

  • PR Newswire2 months ago

    Hikma launches 100th injectable medicine in US with introduction of Vancomycin Hydrochloride for Injection, USP

    "Vancomycin Hydrochloride for Injection is an essential antibiotic used by hospitals to treat patients who have failed to respond to a number of other antibiotics, and it's another important addition to our growing US portfolio," said Dan Motto, Executive Vice President, Commercial and Development, Injectables.

  • Business Wire7 months ago

    Hikma Demonstrates Support for US Pharmacists and Patient Safety

    Activities at upcoming ASHP conference include sponsorship of important symposium advancing patient safety practices

  • Hikma Pharmaceuticals Appoints Kristy Ronco Executive Vice President, Sales and Marketing, Generics
    Business Wire10 months ago

    Hikma Pharmaceuticals Appoints Kristy Ronco Executive Vice President, Sales and Marketing, Generics

    Hikma Pharmaceuticals USA Inc., a wholly owned subsidiary of Hikma Pharmaceuticals PLC , today announced the appointment of Kristy Ronco as Executive Vice President, Sales and Marketing for its Generics Division.

  • Business Wire11 months ago

    Hikma Acts to Ease Critical Shortage of Pain Medications Needed by US Hospitals and Their Patients

    Hikma Pharmaceuticals PLC (the Hikma Group) (HIK.L) (NASDAQ Dubai: HIK) (HKMPY), the multinational generic pharmaceutical company, announced today that its US business has begun releasing significant quantities of hydromorphone to US hospital customers to help ease a current shortage of injectable opioids used to treat patients. In response to this shortage, Hikma released more than five million hydromorphone 2ml vials to US hospitals during June, and expects to release another three million vials during July. The current US hospital shortage of injectable opioids used for patient pain management occurred when a significant supplier to the US market temporarily ceased manufacturing.